4-Bromobiphenyl is a brominated biphenyl that is a colorless solid. It is synthesized by the bromination of biphenyl. 4-Bromobiphenyl is an important industrial chemical, used in the production of pesticides, herbicides, and flame retardants. It is also studied as a potential environmental contaminant, as it can persist in the environment and accumulate in the food chain. Research is ongoing to assess the potential health effects of 4-bromobiphenyl, as it has been linked to endocrine disruption and other adverse effects. It is important to note that 4-bromobiphenyl is a halogenated organic compound, and these compounds are often associated with environmental concerns.'
```
| ID Source | ID |
|---|---|
| PubMed CID | 7101 |
| CHEMBL ID | 1399688 |
| SCHEMBL ID | 4691 |
| MeSH ID | M0107385 |
| Synonym |
|---|
| 4-brombiphenyl |
| smr001224499 |
| MLS002152887 , |
| 4-bromo-1,1'-biphenyl |
| AG-219/25001498 |
| 4-bromo-biphenyl |
| 1-bromo-4-phenyl-benzene |
| 92-66-0 |
| 1,1'-biphenyl, 4-bromo- |
| inchi=1/c12h9br/c13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9 |
| 4-bromobiphenyl |
| nsc406933 |
| 4-bromodiphenyl |
| biphenyl, 4-bromo- |
| p-bromobiphenyl |
| nsc-406933 |
| 4-biphenyl bromide |
| p-phenylbromobenzene |
| NCGC00091652-01 |
| ccris 5890 |
| (4-bromophenyl)benzene |
| p-phenylphenyl bromide |
| ai3-08855 |
| p-bromodiphenyl |
| p-biphenylyl bromide |
| nsc 406933 |
| 4-biphenylyl bromide |
| einecs 202-176-6 |
| 4-bromobiphenyl, 98% |
| 4-bromobiphenyl, technical, >=90% (gc) |
| STK050421 |
| B1330 |
| AKOS000202545 |
| 1-bromo-4-phenylbenzene |
| A844301 |
| EN300-91508 |
| NCGC00091652-02 |
| unii-oe77okh5bl |
| oe77okh5bl , |
| dtxsid4024640 , |
| tox21_200254 |
| NCGC00257808-01 |
| cas-92-66-0 |
| dtxcid804640 |
| 4-(4'-bromophenyl)benzene |
| 4-bromo biphenyl |
| bromobiphenyl(4-) |
| FT-0617875 |
| AM20041411 |
| CX1307 |
| SCHEMBL4691 |
| cid_7101 |
| bdbm74259 |
| 1-bromanyl-4-phenyl-benzene |
| 4-biphenylbromide |
| p-mono-bromobiphenyl |
| 4-bromobipheny |
| 4'-bromobiphenyl |
| Q-200446 |
| 4-brom-biphenyl |
| pbb 3 |
| bromobiphenyl, 4- |
| 4-phenylbromobenzene |
| CHEMBL1399688 |
| PS-7682 |
| mfcd00000100 |
| CS-D1553 |
| AC-10043 |
| pbb-no. 3 10 microg/ml in cyclohexane |
| pbb no. 3 |
| Z57073675 |
| OL10146 |
| Q27285606 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 31.6228 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 35.4872 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.3644 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 20.7466 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 14.1254 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 54.3165 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 39.8107 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 7.9433 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| geminin | Homo sapiens (human) | Potency | 0.1636 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||